製品名:methyl 5-amino-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate

IUPAC Name:methyl 5-amino-4-fluoro-1-methyl-1H-1,3-benzodiazole-6-carboxylate

CAS番号:918321-20-7
分子式:C10H10FN3O2
純度:95%
カタログ番号:CM128230
分子量:223.21

包装単位 有効在庫 価格(USD) 数量
CM128230-5g in stock ǭǟř
CM128230-25g in stock Žţǎ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:918321-20-7
分子式:C10H10FN3O2
融点:-
SMILESコード:O=C(C1=C(N)C(F)=C2N=CN(C)C2=C1)OC
密度:
カタログ番号:CM128230
分子量:223.21
沸点:
MDL番号:MFCD26127252
保管方法:Keep in dark place, store at 2-8°C.

Category Infos

Benzimidazoles
Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

Column Infos

Encorafenib plus Binimetinib
U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products